the public record, side by side

BuSpar (buspirone) vs Vistaril (hydroxyzine)

BuSpar and Vistaril / Atarax, compared on what the public record actually supports: side effects by rate from each FDA label, what the largest trial comparison found, who takes each one, who pays, what the labels warn, and what the litigation record holds. Sources on every number.

the short answer

  • is BuSpar or Vistaril more effective? there is no head-to-head trial record in our library that settles this pair, and we do not fill the gap with a guess. what can be compared is below: each label's own side-effect table, who takes each drug, who pays, and the legal record.
  • which has fewer side effects? the labels say their trials “cannot be directly compared”, because each drug was tested in different people under different rules. what each label prints: BuSpar (buspirone): the label prints no discontinuation rate in the section we transcribed. Vistaril (hydroxyzine): This label contains no placebo-controlled incidence table, no numerical incidence of any kind, and no discontinuation-due-to-adverse-reaction data. There is no statement of trial populations, durations, or denominators, and no "cannot be directly compared" preamble — there is no clinical-trials-experience framework in this label at all. This is consistent with the drug's 1956-era approval predating modern labeling requirements. The hydroxyzine hydrochloride salt form carries the same old-format narrative section — both salt forms lack any drug-vs-placebo comparison.
  • which should i take? not a question this page answers. the odds ratios are averages across thousands of strangers; your history, other medications and what you can live with are not in them. the questions for your prescriber below are built from what is on this page.

What this page will not do is rank them. These drugs are in different classes and were tested for partly different things, so a single-axis ranking would be a category error. Which one fits you turns on your history, your other medications, and side-effect trade-offs — a prescriber conversation. This page arms that conversation; here are the questions worth taking into it →

side effects by rate: what each label prints, not a head-to-head trial

the labels' own warning, first: “The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators.” the two columns below come from different trials, in different people, under different inclusion rules. read each against its own placebo column, not against the other drug.

the two labels list fewer than three reactions under the same name, so there is no side-by-side table here; each label's full table is on the tool page linked below.

  • BuSpar (buspirone): the label prints no discontinuation rate in the section we transcribed.
  • Vistaril (hydroxyzine): This label contains no placebo-controlled incidence table, no numerical incidence of any kind, and no discontinuation-due-to-adverse-reaction data. There is no statement of trial populations, durations, or denominators, and no "cannot be directly compared" preamble — there is no clinical-trials-experience framework in this label at all. This is consistent with the drug's 1956-era approval predating modern labeling requirements. The hydroxyzine hydrochloride salt form carries the same old-format narrative section — both salt forms lack any drug-vs-placebo comparison.
what makes each table, in the labels' words
  • BuSpar (brand discontinued; current generic label) (buspirone), SPL effective 2026-06-15, ADVERSE REACTIONS (old-format label — no numbered 6.1 section). inclusion rule: “TREATMENT-EMERGENT ADVERSE EXPERIENCE INCIDENCE IN PLACEBO-CONTROLLED CLINICAL TRIALS [Events reported by at least 1% of buspirone hydrochloride tablets patients are included.] (Percent of Patients Reporting)” trials: “The table that follows enumerates adverse events that occurred at a frequency of 1% or more among buspirone hydrochloride tablets patients who participated in 4-week, controlled trials comparing buspirone hydrochloride tablets with placebo. The frequencies were obtained from pooled data for 17 trials.” DailyMed
  • Vistaril (pamoate; brand SPL not current — generic label used) (hydroxyzine), SPL effective 2026-06-11, ADVERSE REACTIONS (unnumbered, old-format label), hydroxyzine pamoate capsules, USP (25 mg and 50 mg). DailyMed

every row above was transcribed from the current FDA label on 2026-09-08; the full tables, including the reactions only one label lists, are on side-effect rates, drug vs placebo. the sexual side-effect rows carry each label's own underreporting caveat on the SSRI sexual side effects page.

buspirone (BuSpar)

non-benzodiazepine anxiolytic

FDA approval
1986 · full approval journey →
Who takes it (US, 2024)
3,719,958 patients · 16,718,781 prescriptions (AHRQ MEPS)2014 → 2024: 7,560,250 → 16,718,781 prescriptions, up 121%Correction (29 September 2026): An earlier version of this section took its numbers from ClinCalc DrugStats, a third-party site that republishes this survey; we now compute them from AHRQ’s public-use files ourselves. It showed 3,719,958 people and 16,706,971 prescriptions for 2024; the file gives 3,719,958 and 16,718,781.
Who pays (2024)
Medicare: 7,844,181 claims · 1,553,798 beneficiariesMedicaid: ≥5,245,157 prescriptionsCommercial claims: not published in any public dataset — a real absence, not a zero.
Boxed warning
None on the current FDA label in our record.
Adverse-event reports (FAERS)
Caveat first: FAERS counts unverified REPORTS, not patients or rates — no denominator, and attention inflates reporting. Never compare these counts head-to-head; a longer-marketed, more-prescribed drug accumulates more reports by exposure alone. how to read FAERS →10,969 all-time reports; most-reported terms: fatigue, nausea, headache
Legal & safety record
no dedicated record page yet; the journey page carries label history

hydroxyzine (Vistaril / Atarax)

antihistamine anxiolytic

FDA approval
1956 — before US law required efficacy trials · full approval journey →
Who takes it (US, 2024)
4,680,154 patients · 14,857,241 prescriptions (AHRQ MEPS)2014 → 2024: 7,812,729 → 14,857,241 prescriptions, up 90%Correction (29 September 2026): An earlier version of this section took its numbers from ClinCalc DrugStats, a third-party site that republishes this survey; we now compute them from AHRQ’s public-use files ourselves.
Who pays (2024)
Medicare: 6,278,612 claims · 1,889,798 beneficiariesMedicaid: ≥8,616,838 prescriptionsCommercial claims: not published in any public dataset — a real absence, not a zero.
Boxed warning
None on the current FDA label in our record.
Adverse-event reports (FAERS)
Caveat first: FAERS counts unverified REPORTS, not patients or rates — no denominator, and attention inflates reporting. Never compare these counts head-to-head; a longer-marketed, more-prescribed drug accumulates more reports by exposure alone. how to read FAERS →50,845 all-time reports; most-reported terms: drug ineffective, pruritus, nausea
Legal & safety record
no dedicated record page yet; the journey page carries label history

questions for your prescriber, built from this page

this page does not tell you to start, stop or switch anything. it arms the conversation where that decision belongs. take these in:

  1. which of BuSpar and Vistaril did you have in mind first, and what in my history points that way?
  2. these two are different classes (non-benzodiazepine anxiolytic; antihistamine anxiolytic). what are they each being asked to do for me, and is that use on the label or off it?
  3. the label lists these reactions above placebo for the one you're suggesting. which of them should i expect in the first weeks, and which would make you want to hear from me the same day?
  4. how long were the approval trials, and what do we know past that point?
  5. how will we judge whether it is working, by when, and what is the plan if it isn't?
  6. if i ever want to come off it, how is that done, and over how long?
  7. is there a cheaper generic or a formulation that changes the dosing, and does my insurance prefer one of these two?

the longer checklist, for any antidepressant, is questions to ask before starting antidepressants. if you are already on one and it feels like it stopped working, that has its own page.

What the warnings mean, drug by drug

Each explainer reads one drug's current FDA label and the studies in our library, in both directions: the boxed warnings with the label's own numbers, the trials behind the approval and how long they ran, side effects by rate, and the research since.

Questions people search

Is BuSpar or Vistaril better?

No honest page can answer that in one line. Head-to-head differences between comparable psychiatric medications are usually smaller than rankings suggest, and which fits you depends on your history, other medications, and side-effect trade-offs, a prescriber conversation. What can be compared is the public record (usage, payers, label warnings, approval history, litigation), which is what this page does, with sources.

Is BuSpar the same as buspirone, and Vistaril the same as hydroxyzine?

BuSpar is a brand name for buspirone. Vistaril / Atarax is a brand name for hydroxyzine. buspirone is a non-benzodiazepine anxiolytic; hydroxyzine is an antihistamine anxiolytic. This page uses the generic names because the federal datasets do.

Which has fewer side effects, BuSpar or Vistaril?

The two FDA labels cannot be compared head to head, in their own words, because each drug's trials ran in different people under different rules. What each label prints: BuSpar (buspirone): the label prints no discontinuation rate in the section we transcribed. Vistaril (hydroxyzine): This label contains no placebo-controlled incidence table, no numerical incidence of any kind, and no discontinuation-due-to-adverse-reaction data. There is no statement of trial populations, durations, or denominators, and no "cannot be directly compared" preamble — there is no clinical-trials-experience framework in this label at all. This is consistent with the drug's 1956-era approval predating modern labeling requirements. The hydroxyzine hydrochloride salt form carries the same old-format narrative section — both salt forms lack any drug-vs-placebo comparison. The page shows the reactions both labels list, each against its own placebo column.

Which is prescribed more, BuSpar or Vistaril?

The page shows federal survey estimates we compute from AHRQ’s Medical Expenditure Panel Survey public-use files for both buspirone and hydroxyzine: patients and prescriptions in the latest reliable year, and the yearly series from 2014 where AHRQ’s reliability rule allows it, with a direction stated only when the change is larger than the survey’s margin of error. Prescription volume reflects habits, prices, and marketing as much as evidence, so it is context, not a verdict.

Where these numbers come from

  • Patients and prescriptions: computed by us from AHRQ's public-use Medical Expenditure Panel Survey Prescribed Medicines files, 2014 (HC-168A) to 2024 (HC-254A), with AHRQ's reliability rule (a year with fewer than 60 respondents or a relative standard error over 50% is not shown) — counts of people filling prescriptions, not outcomes. A direction is stated only when the change is larger than the survey's margin of error. Until 29 September 2026 these came from ClinCalc DrugStats, a third-party site; see the correction under each drug where a figure changed.
  • Medicare/Medicaid: CMS public datasets; commercial insurance publishes no per-drug series, so it renders as an absence, never a synthesized number.
  • Label facts: the drugs' current FDA labels via DailyMed — quoted in context on each drug's approval-journey page.
  • FAERS: openFDA — reports, never rates; the caveat travels above every count.
  • Litigation: court records and regulator documents only, on the linked record pages; settled is never adjudicated.

Explore both drugs in depth: /m/buspirone · /m/hydroxyzine · or the whole library →